SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

National Association for Continuing Education
Greg Mattingly, MD
Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
St. Louis, MO
Gregg Sherman, MD
Family Practice
Plantation, FL

: Case Studies in MDD: Individualizing Care
Activity/Course #:
: NCME370
: Free
Release/Start Date:
: Feb 19 2019
Expiration Date:
: Feb 18 2020
: Psychiatry
Target Audience:
: Primary Care Physicians, Nurse Practitioners, Physician Assistants
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.50 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Major depressive disorder (MDD) is a common and disabling condition, associated with high societal costs and greater functional impairment than many other chronic diseases. The economic burden of MDD includes costs to the individual due to emotional suffering, reduced quality of personal relationships, treatment-related adverse effects, costs of medical care, and lost wages; and also costs to society such as loss of life, reduced productivity, and increased costs of mental health and medical care.

Given the high burden of MDD, proper diagnosis and treatment is important. The activity will demonstrate the benefit of using measurement-based tools for assessment of MDD and tailoring treatement strategies to meet individual patient needs.

This webcast was recorded live at the Conversations in Primary Care 2019 and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Implement measurement-based tools for assessing and monitoring symptoms in patients with MDD.
  2. Individualize treatment of MDD based on patient presentation, symptom profile and side effects.
  3. Recognize when switching initial pharmacotherapy is appropriate.
  4. Incorporate shared decision-making strategies into the management of patients with MDD

 How to obtain the CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 contact hour of continuing education which includes 0.50 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Dr. Mattingly has served as a speaker for Allergan, Alkermes, Lundbeck, Merck, Neos, Otsuka, Shire, Sunovion, Takeda, and Vanda. He has served as a consultant for Allergan, Alkermes, Forum, Lundbeck, Merck, Otsuka, Perdue, Rhodes, Shire, Sunovion, Takeda, and Vanda. He conducts research for Akili, Alcobra, Allergan, Alkermes, Boehringer Ingelheim, Forum, Janssen, Medgenigs, NLS-1 Pharma AG, Reckitt Benckiser, Shire, Sunovion, Supernus, and Takeda.

Contributing Faculty
Dr. Andrew J. Cutler has been a consultant for Acadia, Aevi Genomics, Akili Interactive, Alkermes, Allergan, Axsome, Cingulate, IntraCellular Therapies, Ironshore, Janssen, KemPharm, Lundbeck, Neos Therapeutics, Neurocrine, Novartis, Otsuka, Purdue Canada, Sage, Shire, Sunovion, Supernus, Takeda, Teva, Tris Pharma. He has been a Speaker and/or received Promotional Honoraria for: Acadia, Alkermes, Allergan, Lundbeck, Neurocrine, Otsuka, Shire, Sunovion, Takeda, Teva, Tris Pharma.
Research Grants: Acadia, Aevi Genomics, Akili Interactive, Alder, Alkermes, Allergan, Arbor Pharmaceuticals, Axsome, IntraCellular Therapies, Ironshore, Janssen, KemPharm, Lundbeck, Neurocrine, Novatis, Otsuka, Purdue, Sage, Shire, Sunovion, Supernus, Tris Pharma. He is part of the Board for Neuroscience Education Institute

Activity Planning Committe
Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Killbridge, Medical Writer, has no relationship to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationship to disclose.
Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.